{"id":"W4250246459","doi":"10.1200/jco.2017.35.15_suppl.tps4591","title":"S1605: Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; McGill University Health Centre","funders":"","keywords":"Medicine; Atezolizumab; Cystectomy; Bladder cancer; Clinical endpoint; Oncology; Internal medicine; Population; Urology; Immunotherapy; Cancer; Pembrolizumab; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001822386,0.001507286,0.001320152,0.0004208325,0.0002508632,0.0008818288,0.0009972835,0.001877595,0.006812983],"category_scores_gemma":[0.0008263072,0.0004561248,0.00126636,0.00033802,0.0006822649,0.000559787,0.0004466882,0.002713153,0.001776831],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006571709,"about_ca_system_score_gemma":0.001400388,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007067143,"about_ca_topic_score_gemma":0.001713006,"domain_scores_codex":[0.9996402,0.0001732278,0.00002207222,0.0000461102,0.00003786723,0.00008051391],"domain_scores_gemma":[0.9995112,0.00006190842,0.0001129957,0.00003571318,0.00003050523,0.0002476684],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7405949,0.04044139,0.005650455,0.002920645,0.001427995,0.0004180338,0.0002730186,0.003036748,0.04187268,0.0009564135,0.01156828,0.1508393],"study_design_scores_gemma":[0.7779024,0.2094666,0.005115783,0.00008459637,0.0002555815,0.0003006306,0.00003443917,0.001219745,0.002090585,0.0002425013,0.003266887,0.00002024242],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9774061,0.004464017,0.0009557491,0.001159932,0.0004233342,0.005370852,0.00361289,0.0003329793,0.00627414],"genre_scores_gemma":[0.9669173,0.002582931,0.002583019,0.003206994,0.000300042,0.005017675,0.009350684,0.00005685925,0.009984513],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006812983,"threshold_uncertainty_score":0.02279174,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1788530016635562,"score_gpt":0.5346122422509457,"score_spread":0.3557592405873895,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}